5.1 Insurance Policies, Billing & Letters of Medical Necessity

Why finance literacy is a scored Domain 5A skill

Domain 5 (professional practice, finance, legal, and ethics) contributes 39 scored items. Subdomain 5A (7 scored) focuses on insurance policies, billing and reimbursement compliance, and letters of medical necessity (LMNs). On the CGC exam, finance stems are rarely about memorizing a fee schedule. They test whether you can get the right test covered for the right indication, document necessity, and advocate without overpromising.

Coverage barriers are clinical barriers: a delayed hereditary cancer panel, a denied prenatal diagnostic test, or an unpaid consult can change reproductive timing, surgical decisions, and cascade testing. Boards reward counselors who treat insurance navigation as part of competent care—not as “someone else’s job.”

Insurance policies genetic counselors must understand

Payers publish medical policies (coverage criteria) for genetic tests and counseling. Policies differ by plan type (commercial, Medicare, Medicaid, marketplace) and often lag guidelines. Core concepts:

Prior authorization workflow

1. Verify benefits for counseling and the specific test (CPT/panel name, lab).
2. Confirm medical policy criteria (phenotype, family history thresholds, prior negative testing, age/sex rules).
3. Submit PA with clinical documentation (notes, pedigree summary, ICD-10, guideline references).
4. Track determination (approved, denied, pending more info) before irreversible steps when possible.
5. Appeal or pivot (alternate covered test, self-pay options, hardship programs—see 5.3).

Trap: ordering the “best” panel clinically while ignoring a plan’s requirement to use a contracted lab or a narrower covered panel first. Another trap: telling the client “insurance will cover it” before verification.

Lab benefit managers (LBMs)

Many commercial plans outsource genetic-test utilization review to lab benefit managers. LBMs apply proprietary or payer-adopted criteria, may require online portals, and often enforce preferred laboratories. Practically:

• PA may be obtained by the clinic, the lab’s prior-auth team, or both—clarify roles early.
• LBM criteria can be stricter than specialty guidelines; document why the client meets policy language, not only why genetics “makes sense.”
• Peer-to-peer review with a medical director is a common appeal path when the first denial cites “not medically necessary.”

Genetic counselors add value by translating phenotype and pedigree into the exact criteria language LBMs use (e.g., “first-degree relative with epithelial ovarian cancer,” “tumor IHC suggesting Lynch,” “ultrasound anomaly + desire for diagnostic testing”).

Medical necessity criteria for genetic tests

Medical necessity is not the same as clinical usefulness in the abstract. Payers typically want:

• A specific indication (diagnosis, suspected syndrome, established familial variant, guideline-based screening).
• Evidence that the test is not redundant (prior negative appropriate testing considered).
• A clear statement that results will alter management (surveillance, surgery, pregnancy decisions, medication, cascade testing plan).
• Use of a validated methodology appropriate to the indication (e.g., del/dup analysis when indicated; RNA studies when policy allows).

Coding and billing concepts GCs encounter

You are not expected to be a professional coder, but Domain 5A expects fluency with concepts that cause denials:

• CPT codes describe the service (genetic counseling time-based codes where used; molecular pathology codes for tests—often billed by the lab).
• ICD-10 codes must support the indication (Z-codes for family history/genetic carrier status; phenotype codes for symptomatic testing). Mismatch between diagnosis codes and the ordered test is a classic denial trigger.
• Who bills matters: facility vs professional fee; lab billing the molecular CPT; GC services billed under a supervising provider in some settings.
• Documentation must support medical necessity and time/complexity when counseling is billed.
• Compliance: do not upcode indications, invent family history, or order tests solely to generate revenue. Fraud/abuse awareness belongs with professional integrity (Domain 5D) but appears in billing stems as “most appropriate documentation.”

Practical billing pitfalls

• Using a nonspecific ICD-10 when a more precise phenotype or family-history code exists and is required by policy.
• Assuming Medicaid and Medicare follow the same commercial LBM rules.
• Confusing coverage of counseling with coverage of the test—either can be approved while the other is denied.
• Missing that some plans cover only certain genes on a panel and will deny “extras.”

Letters of medical necessity: essential elements

An LMN is a clinician-authored letter (often drafted or co-authored by the GC) that argues why a specific service meets medical necessity. High-yield structure:

1. Patient identifiers and requesting clinician (brief).
2. Clinical indication — phenotype, diagnoses, relevant family history, prior testing and results.
3. Test requested — exact assay/panel/lab; why this test vs narrower/broader alternatives.
4. Guideline / policy support — cite applicable society guidelines, FDA labels when relevant, and map to the payer’s own medical policy criteria language.
5. How the result changes management — surveillance, risk-reducing surgery, pregnancy options, treatment selection, cascade testing—be concrete.
6. Risk of not testing — delayed diagnosis, inappropriate screening, missed relatives, irreversible decisions without information.
7. Closing request — approve coverage / overturn denial; offer peer-to-peer.

Appeals without overpromising

Advocacy language: “Based on your history and this plan’s criteria, we will submit authorization and appeal if denied. Coverage is never guaranteed until the payer issues a determination.” Overpromising (“Don’t worry—they always cover BRCA panels”) is an exam distractor and an ethics risk when the client makes irreversible decisions on that assurance.

Integrated scenarios

Scenario A — hereditary breast cancer: Client meets guideline criteria; commercial plan routes PA through an LBM preferring Lab X. Best next step: verify benefits/PA channel and submit with documentation—not draw for Lab Y “because it’s faster” without checking network rules.

Scenario B — denial: Exome denied as “experimental” despite a child with a clear neurodevelopmental phenotype and nondiagnostic microarray. Best response: LMN mapping phenotype to policy exceptions/guideline support and requesting peer-to-peer—not telling the family the denial means testing has no clinical value.

Scenario C — prenatal: Couple wants diagnostic testing after high-risk NIPT; plan requires PA. Best counseling includes timing honesty: PA delay may push gestational age—discuss parallel self-pay options and urgency without guaranteeing approval.

Common traps

• Ordering before PA when authorization is required and delay is avoidable.
• Writing LMNs that list genes but never explain management impact.
• Confusing clinical guidelines with automatic insurance coverage.
• Guaranteeing payment or coaching clients to misstate history to meet criteria.
• Ignoring LBM/lab channel requirements and blaming “insurance” generically after a preventable denial.

Quick exam checklist

• Benefits verified for counseling and the specific test?
• Policy/LBM criteria mapped to this client’s history?
• PA status known before irreversible lab steps when required?
• LMN includes indication, guideline/policy support, and management change?
• Advocacy framed without coverage guarantees?